Roivant

Pharma

Roivant eyes Humira's throne in NIU after Lisraya ph. 3 win

With the ink barely dry on Lisraya’s first approval, Roivant is wasting little time making the case for a larger immune-mediated kingdom for the drug.

Fraiser Kansteiner Oct 22, 2026 8:04am

Priovant secures 1st FDA nod in rare skin and muscle disease

Aug 27, 2026 9:30pm

settlement lawsuit litigation cash settlement gavel

Moderna commits $950M upfront to resolve patent lawsuit

Mar 4, 2026 10:33am

Amneal and VantAI unveil fresh branding to kick off 2026 plans

Jan 14, 2026 11:40am

Organon's Vtama, Galderma's Nemluvio endorsed by FDA for eczema

Dec 16, 2024 9:00am

Organon pays up to $1.2B to acquire Dermavant and its drug Vtama

Sep 18, 2024 10:09am